Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGPU NASDAQ:IRIX NASDAQ:LNSR NASDAQ:SNWV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.70+7.6%$6.39$1.03▼$32.10$83.85M3.471.86 million shs148,520 shsIRIXIRIDEX$1.13+0.3%$1.08$0.87▼$1.65$19.73M0.64171,839 shs43,978 shsLNSRLENSAR$5.70+1.3%$5.70$5.06▼$13.47$70.01M0.8792,208 shs103,159 shsSNWVSanuwave Health$9.84+14.3%$15.25$7.53▼$46.58$85.98M1.34101,213 shs173,020 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+0.56%+2.73%+387.07%+715,999,900.00%IRIXIRIDEX0.00%-1.31%+7.62%+14.14%+28.41%LNSRLENSAR0.00%-1.57%-2.59%-3.75%-55.72%SNWVSanuwave Health0.00%-6.51%-47.72%-50.49%-71.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.70+7.6%$6.39$1.03▼$32.10$83.85M3.471.86 million shs148,520 shsIRIXIRIDEX$1.13+0.3%$1.08$0.87▼$1.65$19.73M0.64171,839 shs43,978 shsLNSRLENSAR$5.70+1.3%$5.70$5.06▼$13.47$70.01M0.8792,208 shs103,159 shsSNWVSanuwave Health$9.84+14.3%$15.25$7.53▼$46.58$85.98M1.34101,213 shs173,020 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+0.56%+2.73%+387.07%+715,999,900.00%IRIXIRIDEX0.00%-1.31%+7.62%+14.14%+28.41%LNSRLENSAR0.00%-1.57%-2.59%-3.75%-55.72%SNWVSanuwave Health0.00%-6.51%-47.72%-50.49%-71.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGPUPredictive Oncology 1.00SellN/AN/AIRIXIRIDEX 2.00Hold$3.00166.67% UpsideLNSRLENSAR 2.33Hold$10.0074.06% UpsideSNWVSanuwave Health 2.50Moderate Buy$51.00418.56% UpsideCurrent Analyst Ratings BreakdownLatest IRIX, SNWV, LNSR, and AGPU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026SNWVSanuwave Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)6/16/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/4/2026IRIXIRIDEX Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/1/2026LNSRLENSAR Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$10.003/30/2026SNWVSanuwave Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGPUPredictive Oncology$50.29K1,666.36N/AN/A$11.69 per share0.66IRIXIRIDEX$52.67M0.37N/AN/A($0.06) per share-18.75LNSRLENSAR$58.44M1.21N/AN/A($2.18) per share-2.64SNWVSanuwave Health$44.05M1.92$1.94 per share5.07$0.19 per share51.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGPUPredictive Oncology-$233.10M-$8.18N/AN/AN/A-470,383.31%-7,363.67%-626.32%N/AIRIXIRIDEX-$4.44M-$0.19N/AN/AN/A-6.23%-1,204.74%-11.16%8/6/2026 (Estimated)LNSRLENSAR-$34.28M-$0.58N/AN/AN/A50.94%-183.19%42.26%8/6/2026 (Estimated)SNWVSanuwave Health$11.81M$0.3329.71N/AN/A35.96%-450.56%44.87%8/14/2026 (Estimated)Latest IRIX, SNWV, LNSR, and AGPU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026IRIXIRIDEX-$0.07-$0.03+$0.04-$0.03$11.91 million$11.80 million5/15/2026Q1 2026AGPUPredictive OncologyN/A-$0.36N/A-$0.36N/A$0.04 million5/12/2026Q1 2026SNWVSanuwave Health-$0.14-$0.17-$0.03-$0.17$9.60 million$9.62 million5/8/2026Q1 2026LNSRLENSAR$0.1850$1.56+$1.3750N/A$13.40 million$13.43 million3/31/2026Q4 2025AGPUPredictive OncologyN/A$122.75N/A$122.75N/A$0.01 million3/31/2026Q4 2025LNSRLENSAR-$0.10-$0.12-$0.02-$0.12$20.30 million$16.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGPUPredictive OncologyN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGPUPredictive OncologyN/A8.898.89IRIXIRIDEXN/A1.921.19LNSRLENSARN/A2.381.08SNWVSanuwave Health8.151.310.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGPUPredictive Oncology9.04%IRIXIRIDEX20.10%LNSRLENSAR40.15%SNWVSanuwave Health42.53%Insider OwnershipCompanyInsider OwnershipAGPUPredictive Oncology1.21%IRIXIRIDEX8.60%LNSRLENSAR65.80%SNWVSanuwave Health14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGPUPredictive Oncology3010.82 million10.69 millionN/AIRIXIRIDEX12017.41 million15.91 millionOptionableLNSRLENSAR11012.28 million4.20 millionOptionableSNWVSanuwave Health408.60 million7.36 millionN/AIRIX, SNWV, LNSR, and AGPU HeadlinesRecent News About These CompaniesSanuwave Health (NASDAQ:SNWV) Trading Down 11% - What's Next?June 26 at 2:01 AM | americanbankingnews.comSanuwave Health Updates Second Quarter 2026 GuidanceJune 16, 2026 | globenewswire.comSANUWAVE Health Inc (SNWV) Q1 2026 Earnings Call Highlights: Record Revenue Amid Market ChallengesMay 13, 2026 | finance.yahoo.comSANUWAVE Health Balances Growth, Margin Pressure in Q1May 13, 2026 | tipranks.comSanuwave (SNWV) Q1 2026 Earnings TranscriptMay 13, 2026 | fool.comSANUWAVE Health Inc Reports Q1 2026 Results: Full Earnings Call TranscriptMay 13, 2026 | uk.finance.yahoo.comSANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comSanuwave Health Inc. (SNWV) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comSanuwave Announces Revenues and Financial Results for Q1 FY2026May 12, 2026 | globenewswire.comHow The SANUWAVE Health (SNWV) Investment Story Is Shifting Around The US$43.50 TargetMay 12, 2026 | finance.yahoo.comSanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial ResultsMay 6, 2026 | globenewswire.comSanuwave Health Inc. (SNWV) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 1, 2026 | zacks.comHow The SANUWAVE Health (SNWV) Story Is Shifting After The Latest Price Target ResetApril 27, 2026 | finance.yahoo.comSanuwave Health Posts Record Results Amid CMS ShockApril 21, 2026 | theglobeandmail.comSanuwave Health (SNWV) Slipped as CMS Dropped the Coverage LimitApril 20, 2026 | insidermonkey.comSanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-YearApril 16, 2026 | finance.yahoo.comHow The SANUWAVE Health (SNWV) Investment Narrative Is Resetting After A Lower Price TargetApril 13, 2026 | finance.yahoo.comSANUWAVE Health Inc (SNWV) Shares Fall 7.2% -- GF Value Says Still OvervaluedApril 11, 2026 | gurufocus.comSANUWAVE Health (SNWV) price target decreased by 19.44% to 44.37April 9, 2026 | msn.comHow The Reset Price Target Is Rewriting The Story For SANUWAVE Health (SNWV)March 29, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRIX, SNWV, LNSR, and AGPU Company DescriptionsPredictive Oncology NASDAQ:AGPU$7.70 +0.54 (+7.56%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.IRIDEX NASDAQ:IRIX$1.13 +0.00 (+0.27%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.LENSAR NASDAQ:LNSR$5.69 +0.06 (+1.07%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Sanuwave Health NASDAQ:SNWV$9.84 +1.23 (+14.29%) As of 02:16 PM Eastern This is a fair market value price provided by Massive. Learn more.SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Is Apple’s Latest Plunge the Canary in the Coal Mine for Tech Stocks? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
